Tags

Type your tag names separated by a space and hit enter

Effects of eprosartan on target organ protection.
Vasc Health Risk Manag. 2006; 2(1):79-85.VH

Abstract

Hypertension is the most important cardiovascular risk factor for stroke. Blood pressure reduction by antihypertensive treatment is clearly efficacious in the prevention of stroke (both primary and secondary), although no clear differences have yet been observed between antihypertensive drug classes. However, a recent study reported the clear superiority of the angiotensin-receptor blocker eprosartan over the calcium channel blocker nitrendipine in cardiovascular protection of hypertensive patients with a previous stroke. Comparative studies using angiotensin-receptor blockers have also suggested the superiority of this class of drugs on primary stroke prevention. This effect may be linked to their beneficial actions on left ventricular hypertrophy, atrial enlargement, and supraventricular arrhythmias, endothelial dysfunction, inflammation, and remodelling, as well as a direct neuroprotective effect mediated through the stimulation of the angiotensin II type-2 receptor. In addition, a sympathoinhibition observed with the renin-angiotensin system blockers and particularly demonstrated with eprosartan, may help to explain the better cardiovascular and cerebrovascular protection in comparison with the calcium antagonist nitrendipine.

Authors+Show Affiliations

Hypertension Unit, Department of Internal Medicine, Hospital Clinic, IDIBAPS, University of Barcelona, Spain. asierra@clinic.ub.es

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17319472

Citation

de la Sierra, Alejandro. "Effects of Eprosartan On Target Organ Protection." Vascular Health and Risk Management, vol. 2, no. 1, 2006, pp. 79-85.
de la Sierra A. Effects of eprosartan on target organ protection. Vasc Health Risk Manag. 2006;2(1):79-85.
de la Sierra, A. (2006). Effects of eprosartan on target organ protection. Vascular Health and Risk Management, 2(1), 79-85.
de la Sierra A. Effects of Eprosartan On Target Organ Protection. Vasc Health Risk Manag. 2006;2(1):79-85. PubMed PMID: 17319472.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of eprosartan on target organ protection. A1 - de la Sierra,Alejandro, PY - 2007/2/27/pubmed PY - 2007/3/22/medline PY - 2007/2/27/entrez SP - 79 EP - 85 JF - Vascular health and risk management JO - Vasc Health Risk Manag VL - 2 IS - 1 N2 - Hypertension is the most important cardiovascular risk factor for stroke. Blood pressure reduction by antihypertensive treatment is clearly efficacious in the prevention of stroke (both primary and secondary), although no clear differences have yet been observed between antihypertensive drug classes. However, a recent study reported the clear superiority of the angiotensin-receptor blocker eprosartan over the calcium channel blocker nitrendipine in cardiovascular protection of hypertensive patients with a previous stroke. Comparative studies using angiotensin-receptor blockers have also suggested the superiority of this class of drugs on primary stroke prevention. This effect may be linked to their beneficial actions on left ventricular hypertrophy, atrial enlargement, and supraventricular arrhythmias, endothelial dysfunction, inflammation, and remodelling, as well as a direct neuroprotective effect mediated through the stimulation of the angiotensin II type-2 receptor. In addition, a sympathoinhibition observed with the renin-angiotensin system blockers and particularly demonstrated with eprosartan, may help to explain the better cardiovascular and cerebrovascular protection in comparison with the calcium antagonist nitrendipine. SN - 1176-6344 UR - https://www.unboundmedicine.com/medline/citation/17319472/Effects_of_eprosartan_on_target_organ_protection_ L2 - https://dx.doi.org/10.2147/vhrm.2006.2.1.79 DB - PRIME DP - Unbound Medicine ER -